Parabilis Medicines

📅 Upcoming

🕒 Recent(90d)

News

• ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
  Two RNA biotechs, ADARx Pharmaceuticals and City Therapeutics, are taking advantage of the IPO frenzy, which has led to a total of 27 newly public biotechs so far this year.
  biospace · 9d ago
• Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
  Iambic Therapeutics is maintaining the momentum generated by its recent mega round and Big Pharma partnerships by gearing up to go public.
  fiercebiotech · 13d ago
• Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
  Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals are the latest biotechs to set out plans to go public this year.
  fiercebiotech · 14d ago
• Inflammation biotech Electra charges up with $350M from upsized IPO
  Electra Therapeutics is the latest biotech to overshoot its own IPO expectations this year, with the inflammation-focused company bringing in $350 million from this morning’s Nasdaq listing.
  fiercebiotech · 17d ago
• Electra aims for $342M IPO to power inflammatory drug’s push through phase 3
  Electra Therapeutics is hoping to raise up to $341.9 million from an IPO in order to power the clinical development of its inflammatory disorder drug, ipsoprubart.
  fiercebiotech · 20d ago
• BrainChild Bio targets deadly pediatric brain cancer with $116M series A
  BrainChild Bio’s lead asset BCB-276 is in pivotal development for diffuse intrinsic pontine glioma, a rare and fatal brain tumor that affects around 300 children in the U.S. every year.
  biospace · 26d ago
• AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies
  ADARx has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing clinical trials of a range of next-gen small interfering RNA medicines.
  fiercebiotech · 28d ago
• JATT mastermind launches latest biotech-focused SPAC via $60M IPO
  Just two months after Someit Sidhu, M.D., succeeded in pairing off his second special purpose acquisition company (SPAC) with Talawar Therapeutics, the biotech entrepreneur is back at it again.
  fiercebiotech · 1mo ago
• Biotech IPOs approach ‘escape velocity’ barring yellow flags that could threaten rebound
  Twenty-five biotechs have used the IPO route to go public this year—with five of those debuts occurring this month alone. It’s the most IPOs since 2021, when the industry recorded 78 during the hei…
  biospace · 1mo ago
• Young startups miss out on biotech venture funding rebound, MassBio says
  A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in opposite directions, as funding slows for young companies with the “riskiest…
  biopharma_dive · 1mo ago